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A TCR Binds to Antagonist Ligands with
Lower Affinities and Faster Dissociation
Rates Than to Agonists
Daniel S. Lyons,* Stephanie A. Lieberman,‡ binding between agonist peptide–MHC complexes and
TCR have now been characterized by several groupsJohannes Hampl,† J. Jay Boniface,*
Yueh-hsiu Chien,* Leslie J. Berg,‡ (Corr et al., 1994; Sykulev et al., 1994a, 1994b; Matsui
et al., 1994). Of particular relevance here is the reportand Mark M. Davis*†
*Department of Microbiology and Immunology of Matsui et al. (1994), which employed surface plasmon
resonance to analyze the interaction of a soluble form†The Howard Hughes Medical Institute
Stanford University School of Medicine of the 2B4 TCR (Lin et al., 1990) with its ligand, a moth
cytochrome c (MCC) peptide bound to the mouse classStanford, California 94305-5402
‡Department of Molecular and Cellular Biology II MHC molecule Ek (Wettstein et al., 1991). It was found
that the most stimulatory ligand (MCC–Ek) had the lon-Harvard University
Cambridge, Massachusetts 02138 gest half-life of binding to the TCR (z12 s), while the
least stimulatory ligand (T102S–Ek) had the shortest half-
life (z2–4 s); thus, agonist activity correlated with the
dissociation rate of TCR from the peptide–Ek complex.Summary
Matsui et al. (1994) speculated that antagonist pep-
tide–Ek and TCR complexes might have even shorterT lymphocyte activation is mediated by the interaction
half-lives, and that this parameter might determine theof specific TCR with antigenic peptides bound to MHC
whole range of T cell responsiveness. Here, we reportmolecules. Single amino acid substitutions are often
binding measurements of three antagonist peptide–Ekcapableof changing the effect of a peptide from stimu-
complexes with the 2B4 TCR. We find that all threelatory to antagonistic. Using surface plasmon reso-
complexes show significantly lower binding affinity tonance, we have analyzed the interaction between a
the 2B4 TCR as compared with agonist and weak ago-complex consisting of variants of the MCC peptide
nist/peptide–MHC complexes. This decrease in affinitybound to a mouse class II MHC (Ek) and a specific
is largelydue to an increase in the off-rateof thepeptide–TCR. Using both an improved direct binding method
MHC complex from the TCR. This suggests that theas well as a novel inhibition assay, we show that the
stability of the ternary complex between TCR and aaffinities of three different antagonist peptide–Ek com-
given peptide–MHC is a major determinant of T cellplexes are z10–50 times lower than that of the wild-
responsiveness.type MCC–Ek complex for the TCR, largely due to an
increased off-rate. These results suggest that the bio-
logical effects of peptide antagonists and partial ago- Results
nists may be largely based on kinetic parameters.
Biological Activity of MCC Peptide Analogs
Introduction The 2B4 T cell hybridoma recognizes a MCC peptide in
association with the mouse class II MHC molecule I-Ek.
In the past several years, many variants of T cell anti- In this system, the variant peptides T102S (Matsui et al.,
genic peptides have been found that can change an 1994) and T102N (Reay et al., 1994) are weak agonists
agonist ligand into one capable of either inhibiting a and K99Q is a weak antagonist (Spain et al., 1994). As
wild-type response (antagonism) or causing only partial originally suggested by surveys with other cytochrome-
activation of T cells. Such variant peptides may provide reactive T cells (Page et al., 1994; P. A. Reay et al.,
important insights into the mechanics of TCR engage- unpublished data), we find that K99R and T102G are
ment and early events in T cell activation. They may also even more robust antagonists in this system (Figures
help shape immune responses by blocking autoimmune 1A and 1B). All of the peptides studied here, including
diseases, providing a means by which viruses escape the null peptides K99A and K99T (Figures 1A and 1B),
from immunosurveilance, and promoting positive selec- bind to Ek with similar affinity (Reay et al., 1994), indi-
tion of thymocytes in vitro (reviewed by Sette et al. 1994; cating that the observed differences in their ability to
Jameson and Bevan, 1995; Sloan-Lancaster and Allen, elicit T cell responses are due to alterations solely in
1996). the interactions between the TCR and peptide–MHC
The differences in signaling through the T cell antigen complex.
receptor (TCR) by a major histocompatibility complex The question of how these antagonist peptide–MHC
(MHC) molecule complexed with agonist versus antago- complexes interact with the 2B4 TCR was then ad-
nist peptides could be of a qualitative or a quantitative dressed in two different ways: by direct measurements
nature. In the former category, it has been suggested of peptide–MHC binding to immobilized TCR and by a
that differences in TCR conformation induced by a pep- newly developed competitive binding assay.
tide–MHC complex could determine anagonist or antag-
onist response (Yoon et al., 1994). In the latter, differ-
ences in the kinetics of TCR binding to peptide–MHC Binding of MHC–Peptide Complexes to TCR
as Measured Directly with Cysteine-Coupled TCRmight be responsible for a positive or negative signal
being propagated (Rabinowitz et al., 1996; Jameson and Our initial attempts to measure antagonist peptide–Ek
complexes binding to TCR-coated biosensor surfacesBevan, 1995; Kersh and Allen, 1996). The kinetics of
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Figure 1. Activation and Antagonism of the
2B4 Hybridoma by MCC Peptide Analogs
(A) 2B4 hybridoma cells were stimulated with
Ek expressing CHO cells and the indicated
concentrations of either wild-type MCC (open
squares),T102S (opendiamonds),K99T (open
circles), K99A (closed triangles), K99R
(pluses), or T102G (open inverted triangles)
peptide, and IL-2 levels were measured.
K99Q (data not shown) is also nonstimulatory.
(B) Antagonist activity of analogs K99R
(closed circles), T102G (closed diamonds),
K99Q (open triangles), or K99T (open circles)
was assessed by adding increasing concen-
trations of each peptide and 2B4 hybridoma
cells to Ek expressing CHO cells prepulsed
with 0.005 mM MCC peptide. The percent in-
hibition with each analog peptide is shown,
and similar results were obtained in at least
five independent experiments, some of which
were done by mixing MCC and the antagonist
peptides instead of prepulsing.
resulted in no detectable signal. Reasoning that a sub- epitope in the cysteine-coupled TCR. One other differ-
ence between the two systems was that the concentra-stantial amount of TCR was being inactivated by the
NHS/EDC coupling of free amine groups, we decided tions of MCC–Ek used in experiments with cysteine-
coupled TCR in general were lower than those used withto attempt an oriented coupling of the 2B4 TCR through
the exposed thiol in the constant region of the b chain amine-coupled TCR (Matsui et al., 1994), because of the
increased sensitivity. We noted that on-rates decreased(Bentley et al., 1995). This should allow a much larger
percentage of the surface to be accessible for binding slightly as concentrations of peptide–MHC were in-
creased in the dose reponse (Figure 2A), and thus theby peptide–MHC.
Immobilizing the TCR in this way resulted in approxi- observed KD value may be dependent upon the concen-
tration of peptide–MHC in solution during binding. Themately a 2- to 4-fold increase in signal compared with
theamine-coupling method when similarconcentrations observation that immobilization chemistry can alter the
kinetics has also been observed in other systems, suchof MCC–Ek were injected over the surfaces. Clear bind-
ing was also detectable at much lower concentrations as in MHC class I binding to immobilized peptides
(Khilko et al., 1993).of MCC–Ek as is seen in the dose response of Figure
2A in comparison to that of Matsui et al. (1994). Fitting Binding to the cysteine-coupled TCR was highly spe-
cific, as K99A–Ek (a null peptide–MHC complex whichof the association phase (Figure 2B) and dissociation
phase (Figure 2C) using the nonlinear fitting routines in is neither an agonist nor an antagonist) elicited no de-
tectable signal (Figure 3A) at a concentration similar toBIAEvaluation 2.1 (Pharmacia Biosensor) gives equilib-
rium dissociation constant (KD) values that are some- that of MCC–Ek used in the dose response. We also
tested the weak agonist T102S–Ek (Figure 3A) and foundwhat lower than those reported previously (Matsui et
al., 1994). The major source of the difference in affinity that while the on-rate of binding to 2B4 TCR (Figure 3B)
is almost identical to that of MCC–Ek, the off-rate (Figure(from 90 mM to around 40 mM) between amine-coupled
and cysteine-coupled TCR is the on-rate, which changes 3C) is about 6-fold faster, consistent with previous ob-
servations (Matsui et al., 1994). The association phasefrom 900 M21s21 to 1600 M21s21. This difference may
reflect an increased availability of the complete binding is now clearly observed, which was not possible using
TCR Binding to Antagonist Peptide–MHC Ligands
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Figure 2. MCC–Ek Binding to Cysteine-Cou-
pled TCR
(A) MCC–Ek complexes were passed over
TCR coupled to the sensor chip (see Experi-
mental Procedures) via the free cysteine in
the b chain constant region. MCC–Ek was in-
jected at concentrations of 0.19, 0.38, 0.77,
1.5, and 3.1 mg/ml. The association (B) and
dissociation phases (C) were fit using the sin-
gle-site binding model of BIAEvaluation 2.1
(Pharmacia Biosensor). Data points are dis-
played (open squares) with the fitted curves
overlaid (lines). The residuals (the difference
between fitted curve and data curve at each
timepoint) are plotted below each curve as
an estimate of the error. These plots are rep-
resentative of five independent experiments.
the amine-coupled surface. In addition, another weak for specificity, a monoclonal antibody (MAb) D-4, which
recognizes particular cytochrome c peptide–Ek com-agonist, T102N, which is slightly less stimulatory than
T102S (Reay et al., 1994), exhibited similar kinetics, with plexes (P. A. Reay and M. M. D., unpublished data), was
able to reduce binding down to the background levela slightly faster off-rate of 0.44 s21 (Table 1).
This improved sensitivity of the cysteine-coupled TCR found with K99A–Ek for both K99R–Ek and T102G–Ek
(data not shown). Because this antibody covers thesuggested that specific binding might be measurable
with antagonist peptide–MHC complexes. Therefore, binding domain of the peptide–MHC complex, it serves
as an effective inhibitor.K99R–Ek (Figure 4A) and T102G–Ek (Figure 4B) were
tested for binding to the TCR surface at varying concen- The dissociation rate was first estimated by fitting
the dissociation phase of the binding curve to a singletrations, using the null peptide (K99A–Ek) complex as a
control. These two antagonist–Ek complexes consis- exponential. This gives an off-rate in the range of 1.0–3.0
s21 for K99R–Ek and T102G–Ek at flow rates of 15 or 30tently showed higher levels of signal at equilibrium in
comparison to K99A–Ek, indicative of specific binding ml/min, but the absolute accuracy of these numbers is
questionable, as there is always a time at the beginningwith rapid kinetics. Taking the difference between the
null peptide K99A–Ek signal (arising from nonspecific of the dissociation phase when the flowcell is not com-
pletely exchanged into running buffer. This time is di-changes in refractive index upon injection of protein) and
that of the antagonist peptide–Ek complexes allowed us rectly proportional to the flow rate. Therefore, to improve
the accuracy of these measurements, we used the tech-to calculate the amount bound at equilibrium. Fitting a
plot of this amount bound versus the concentration of nique of van der Merwe et al. (1994), in which initial off-
rates are determined over a series of increasing flowpeptide–Ek complex (Figure 4C) to an equilibrium bind-
ing model gave KD values of 500 mM for K99R and 1500 rates. This allows us to extrapolate to an infinite flow
rate, where the time of washout approaches zero. A plotmM for T102G, as summarized in Table 2. By the same
approach, KD values of 70 mM and 150 mM were deter- of the apparent dissociation time versus the inverse of
the flow rate gives a linear curve with the y interceptmined for MCC–Ek and T102S–Ek, respectively (Table 2).
The close agreement between these values and those equivalent to the dissociation time at infinite flow rate.
Only the first 1–4 s of the dissociation curve were fit todetermined earlier provides further evidence for the va-
lidity of this equilibrium method. As an additional control a single exponential to calculate the dissociation time
Immunity
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Figure 3. T102S–Ek Binding to Cysteine-
Coupled TCR
(A) T102S/Ek (solid line) was passed over cys-
teine-coupled 2B4 TCR at concentrations of
3.1, 4.6, 6.1, 7.07, and 8.0 mg/ml. The null
peptide K99A/Ek (dotted line) was also in-
jected at 8.0 mg/ml as a reference for the
background level of signal. Association (B)
and dissociation (C) curve fitting is displayed
as in Figure 2. These results are representa-
tive data from two independent experiments.
(which is equivalent to the inverse of the koff) using BIAE- dissociation rate or some combination of the two. In this
case, however, it is most likely due to a much faster off-valuation 2.1 (Pharmacia Biosensor) for either bovine
serum albumin (BSA), K99R–Ek, or T102G–Ek (fitting not rate, for the following reasons. First, as seen in Table
1, all of the cytochrome c–Ek complexes have on-ratesshown). A comparison of the y intercept values gave koff
values of 4.8 s21 for K99R–Ek and 5.1 s21 for T102G–Ek no slower than 600 M21 s21, and it seems likely that the
K99Q–Ek complex would fall into this range as well. By(Figure 4D). By comparison BSA exhibited a koff value
of 7.5 6 0.9 s21. The association rate constant (kon) is this argument, the lack of binding is unlikely to be due
to a slowing of the on-rate. Second, if the off-rate wasdifficult to measure directlydue to the rapiddissociation,
but as kon 5 (koff / KD), we can estimate this as 9600 the same or slower than the other two antagonists, we
should have detected at least some specific dissociationM21s21 for K99R and 3400 M21s21 for T102G, respectively
(Table 2). from the TCR. Because we cannot detect this even at
the higher concentrations and the affinity of K99Q–EkThe K99Q–Ek complex showed no interaction with the
2B4 TCR above the level of the null complex K99A–Ek, differs from T102G–Ek by a factor of only 2 (see below,
Table 3) the dissociation rate is probably even fastereven at concentrations as high as 18.5 mg/ml. Formally,
this could be due to a slower association rate or a faster than that of K99R–Ek and T102G–Ek (> 5.1 s21).
Table 1. Direct Binding to Immobilized 2B4 TCR
Peptide Coupling kon (M21s21) koff (s21) KD (mM)
MCC (agonist) amine 600 0.057 90
PCC (agonist) amine 1105 0.09 80
MCC (agonist) cysteine 1600 6 810 0.063 6 0.009 40 6 21
MCC (T102S) (weak agonist) cysteine 1500 6 360 0.36 6 0.018 240 6 60
MCC (T102N) (weak agonist) cysteine 1400 6 730 0.44 6 0.020 320 6 90
2B4 and peptide–Ek apparent binding constants. The data on MCC and PCC–Ek binding to amine-coupled 2B4 TCR are from Matsui et al.
(1994), after correction for the change in extinctioncoefficient (see text). All values represent the mean of at least three independent experiments,
with the exception of T102S and T102N, which are from two independent experiments.
TCR Binding to Antagonist Peptide–MHC Ligands
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Figure 4. Direct Binding of Peptide–MHC Complexes to Immobilized TCR
(A) K99A (dotted line) and K99R–Ek (solid line) complexes were injected over the 2B4 TCR surface at concentrations of 5.1, 7.7, and 11.5
mg/ml.
(B) T102G and K99A–Ek complexes were injected over either a control blank flow cell (thin lines) or over the cysteine coupled TCR (thick lines
for T102G) and (broken lines for K99A) as in (A) at concentrations of either 29 or 9.2 mg/ml.
(C) The observed equilibrium level of bound peptide–MHC (obtained by taking the difference between the MCC, K99R, or T102G signal at
equilibrium and the K99A signal) is plotted against concentration of either MCC (open squares), K99R (open circles), or T102G/Ek (open
triangles) complexes. The fit of these curves to an equilibrium binding model (steady-state fit model in BIAEvaluation 2.1) is also displayed
(thin lines). This figure is representative data from three independent equilibrium binding experiments.
(D) The calculated dissociation times (1/koff) for the K99R and T102G–Ek complexes and for BSA are plotted against 1/flow rate. After linear
fitting of each curve, the y intercept gives the dissociation time. The observed fitting is averaged from two independent determinations. The
fits give intercepts of 0.206, 0.197, 0.134, which yield koff values of 4.8, 5.1, and 7.5 s21 for K99R–Ek, T102G–Ek, and BSA, respectively.
A Competitive Binding Assay for Measuring peptide can be coupled to a biosensor chip in a manner
that allows efficient binding to soluble TCR in a peptide-TCR Affinities
Another approach to measure the affinity of weak inter- specific manner.
In this application, detergent-solubilized MCC-loadedactions using the BIAcore (Pharmacia Biosensor) instru-
ment is to utilize a competitionassay. This should extend Ek was immobilized on the sensor chip, and soluble 2B4
TCR was then passed over the surface either alone orthe sensitivity of the instrument even further, as was
seen by Takemoto et al. (1996) in studying the interac- with competitor peptide–MHC complexes. A clear dose-
dependent decrease in the amount of TCR bound wastions of hemagglutinin with its cell surface receptor. To
develop such an assay, we took advantage of the recent observed when TCR was preincubated with soluble Ek
complexed with MCC (Figure 5A), T102S, K99R (Figureresults of J. H. et al. (unpublished data), who have shown
that detergent-solubilized native Ek complexed with 5B), K99Q (Figure 5C), and T102G peptides. In contrast,
Table 2. Steady-State Analysis
Peptide Coupling kon (M21s21) koff (s21) KD (mM)
MCC (agonist) cysteine N/A N/A 70 6 5.0
MCC (T102S) (weak agonist) cysteine N/A N/A 150
MCC (K99R) (antagonist) cysteine (9600) 4.8 6 0.80 500 6 260
MCC (T102G) (antagonist) cysteine (3400) 5.1 6 0.90 1500 6 800
MCC (K99Q) (weak antagonist) cysteine — . 5.1 —
Values for koff were obtained from fitting the data in Figure 6D (from two independent experiments), and the KD values were obtained from
steady-state fitting of equilibrium binding curves (Figure 6C) from three independent experiments as described in Experimental Procedures.
The values for kon are in brackets to indicate that they were calculated based on the experimentally determined KD and koff values.
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Table 3. Solution Inhibition Assay
Peptide c0 c1 c2 IC50 (mM) KD (mM)
MCC 83.5 6 1.1 277.9 6 0.004 0.10 6 0.004 8.1 N/A
T102S 67.6 6 4.0 259.0 6 0.005 0.025 6 0.005 48 240
K99R 70.3 6 4.0 263.1 6 3.7 0.02 6 0.003 66 330
T102G 65.8 6 6.1 256.3 6 6.7 0.005 6 0.002 240 z880–1200
K99Q 60.3 6 16 262.1 6 12 0.004 6 0.003 420 2080
The inhibition curves in Figure 5 were fit to a single exponential equation of the form: percent inhibition 5 c0 1 c1 * exp (2c2*(concentration
peptide–MHC). Estimates of the error in the competitive binding experiment may be made from the standard error in the fitting parameters
c0, c1, c2. The KD values were calculated from the observed IC50 as described in Experimental Procedures. The KD value for T102G–Ek shows
a range of possible values, dependent upon whether its inhibition curve was extrapolated to 65% or 100%.
the null peptide K99A complexed with Ek (Figure 5D) experiments, where applicable. The ability to measure
a KD value for K99Q–Ek shows that this competitionand empty Ek molecules (data not shown) exhibited no
inhibition. The degree of inhibition depended on the method can significantly extend the range of theBIAcore
(Pharmacia Biosensor) instrument beyond the directconcentration of competitor peptide–Ek complex, with
50% inhibition (IC50) values estimated from the fit of the binding method, where this complex showed no detect-
able binding.curves in Figure 5E (see Experimental Procedures). As
shown in Table 3, these measurements yield equilibrium
dissociation constants of 330 mm for T102S, 330 mM Discussion
for K99R, 880–1200 mM for T102G (which seems to ag-
gregate at lower concentrations than any of the other Thus, as summarized in Tables 1, 2, and 3, it appears that
the agonist peptide–MHC complexes in general have acomplexes), and 2080 mM for K99Q. These values are
all in reasonably good agreement with the direct binding higher affinity (or lower KD) for the 2B4 TCR and slower
Figure 5. Solution Inhibition of TCR Binding
to Immobilized MCC/Ek
The dissociation phase is plotted for 2B4 TCR
binding to detergent-solubilized MCC–Ek. RU
are plotted against time for TCR binding in
the presence of varying concentrations of ei-
ther (A) MCC, (B) K99R, (C) K99Q, or (D) K99A
complexed to soluble GPI-linked Ek. The
baselines are corrected such that the end of
the sensorgram is 0 RU, and levels of inhibi-
tion are calculated by comparing the number
of RU bound at a given timepoint versus the
number of RU bound without inhibitor. Each
plot contains the TCR alone curve (open dia-
monds) with each lower curve showing a de-
creasing amount of binding as the concentra-
tion of competitor peptide–MHC is increased.
The concentrations are 0.09, 0.23, 0.85, and
3.2 mg/ml in (A), 1.15, 2.3, 14.8 mg/ml in (B),
6.9 and 32.6 mg/ml in (C), and 15.5 mg/ml in
(D). (E) The percentage inhibition is plotted
against the concentration of inhibitor to ob-
tain an IC50 value for MCC (open squares),
T102S (closed triangles), K99R (open circles),
T102G (closed diamonds), and K99Q (open
inverted triangles).K99A/Ek is shown (closed
squares) as a negative control. An exponen-
tial fit to the data is shown (thin line) for each
peptide, and for T102G this fit was extrapo-
lated to 65% inhibition from early data points
(broken line).
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Experimental Proceduresoff-rates than antagonist complexes. In this subline of
the 2B4 hybridoma, the CD4 coreceptor is not present
T Cell Activation Assayto any significant extent, allowing us to concentrate on
The 2B4 hybridoma (Hedrick et al., 1982) was used for T cell activa-
the interactions between the TCR and peptide–MHC tion assays in which 5 3 104 2B4 hybridoma cells were cultured
alone. with 5 3 104 Ek-expressing Chinese hamster ovary (CHO) cells and
varying concentrations of the MCC peptide (88–103) (sequence ANEThe approximate range of KD values for partial agonist
RADLIAYLKQATK) or the indicated peptide analogs. Antagonismpeptide–Ek complexes appears to be around 100–250
assays were done either by mixing the peptides as described inmM (very similar to the lower limit for stimulation re-
Spain et al. (1994) or by prepulsing the antigen-presenting cells forported in another T cell recognition system by Sykulev
2 hr with 0.005 mM MCC peptide, washing, and then exposing them
et al. [1994a]). The range for antagonist peptide–Ek com- to varying concentrations of peptide analogs with 2B4 hybridoma
plexes begins around 250–500 mM for K99R–Ek and ex- cells. Both methods gave identical results. After 24 hr of culture,
supernatants from duplicate cultures were harvested, and interleu-tends to at least 2100 mM for K99Q–Ek. The dissociation
kin-2 (IL-2) was quantitated by titration on HT-2 indicator cells (Wat-rates for K99R, K99Q, and T102G of z5.0 s21 or more
son, 1979). One U/mlcorresponds to one-tenth maximal proliferationare much faster than those of the agonist ligands, which
of the indicator cells. For antagonist assays, the percent inhibitionrange from 0.06–0.44 s21. That there is only a 2-fold
was calculated as: 100 2 100*(IL-2 concentration in the presence /
difference in affinity between the weak agonist and the IL-2 concentration in the absence) of the MCC peptide analog.
highest affinity antagonist suggests that dissociation
rate is a better predictor of a T cell response. Similarly, Peptides
MCC (88–103) and K99R (93–103), peptides were synthesized bythe finding that T102G and K99R have almost the same
the Tufts University Medical School Microchemistry Facility. Theantagonist activities (Figure 1) and nearly identical dis-
peptides T102S (88–103), K99T (93–103), and K99A(88–103) weresociation rates, but differ z3-fold in affinity (Table 2),
obtained from the Proteinand Nucleic Acid (PAN) Facility at Stanford
also supports this conclusion. Several mechanisms can University. The T102G MCC (88–103) peptide was synthesized in
be invoked to explain this dependence on dissociation the laboratory of Dr. H. McConnell. Initial experiments with K99R
rate. One suggests that peptide–MHC ligands that bind (88–103) were done with peptide given by Dr. A. Sette and gave
identical results when compared with the later material. All peptidesto the TCR less stably would disrupt the formation of
were high pressure liquid chromatography purified prior to use.TCR oligomers, which appears to be necessary for T
For BIAcore binding studies the following additional peptides K99Rcell activation (Sette et al., 1994; Brown et al., 1994;
(88–103 acetylated N terminus), K99Q (88–103), MCC (88–103),
Koenig et al., 1995). Another possibility is that rapid T102G (88–103), K99A (88–103 plus 2 D alanine residues at C termi-
dissociation could change the nature of the signal deliv- nus), and T102N (88–103) were synthesized by the PAN facility at
ered by the T cell receptor. Rapid dissociation might Stanford University.
allow only unproductive initial phosphorylation reac-
Protein Purificationtions of the CD3 complex, as observed by Sloan-Lan-
Native Ek was prepared by detergent lysis of CH27 B cell lymphomascaster et al. (1994) and Madrenas et al. (1995). Long-
or from transfected Ek–CHO cells and purified by affinity chromatog-lived complexes, on the other hand, would allow the
raphy on a 14-4-4 MAb column as described (Buus et al., 1986;
entire signal transduction pathway to be completed, Schild et al., 1994). Fractions containing Ek were pooled and pep-
resulting in T cell activation. This is consistent with the tides were loaded according to modifications of published proce-
kinetic proofreading model proposed by McKeithan dures (Matsui et al., 1994; Boniface and Davis, 1996). Purity and
biological activity of the prepared peptide–Ek complexes was deter-(1995) and extended by Rabinowitz et al. (1996). This
mined by nonreducing SDS–PAGE, ELISA utilizing the MAbs 14-4-4model suggests that the multiple reactions in the signal
(anti-Ek) and D-4 (anti-Ek/MCC88–103) (P. Reay and M. M. D., unpub-transduction machinery of the T cell could amplify differ-
lished data), and T cell activation assays with plate bound MCC–Ek
ences in affinity between agonist and antagonist ligands complex (Kane et al., 1989; Schild et al., 1994). The efficiency of
for the TCR, increasing the specificity of the system for peptide loading was estimated to be around 25% for the MCC–Ek
agonist ligands, and that the fast off-rates of antagonist complex as determined by ELISA with 14-4-4 and D-4 (data not
shown).ligands may be critical for their function. We would fur-
Soluble GPI-linked 2B4 TCR was prepared according to Lin et al.ther suggest a “substrate depletion” model, in which
(1990) with the following modifications. Following cleavage fromsome intermediate required for normal T cell activation
CHO cells expressing GPI-linked TCR, harvests were affinity purified
is depleted by the engagement of a TCR by antagonist on both an A2B4 (anti-Ca) antibody followed by an H57 (anti-Cb)
peptide–MHC complexes, thus weakening the ability of antibody (Kubo et al., 1989) column. The resulting TCR was then
agonist peptides to trigger a response. This critical sub- size purified on a Superdex-200 size exclusion column (Pharmacia).
The protein concentration was determined by absorbance at 280strate could be CD3z-associated molecules or one or
nm using an extinction coefficient of 1.3 (mg/ml)21cm21.more of the other intermediates in TCR activation. The
Soluble GPI-linked Ek was prepared as described by Wettstein etfaster off-rates of the antagonist and weak agonist pep-
al. (1991). GPI-linked Ek complexes for all BIAcore experiments were
tide–Ek complexes in comparison to strong agonists prepared as described earlier (Matsui et al., 1994; Boniface and
would allow them to engage more TCR molecules via Davis, 1996). Protein concentration was determined by absorbance
serial engagement (Vallitutti et al., 1995) and thus more at 280 nm using an extinction coefficient of 1.3 (mg/ml)21cm21 de-
rived from amino acid composition analysis. It should be noted thatrapidly deplete a limiting substrate. Although the gener-
this is a correction from the previous estimate of 2.0 (mg/ml)21cm21ality of the progression seen here may differ in other
(Matsui et al., 1994).systems (for example see an anomalous agonist peptide
described by Al-Ramadi et al. [1995]), our results indi-
Binding Analysis Using Immobilized TCR
cate that within this particular T cell recognition model 2B4 TCR was immobilized using 2-(2-pyridinyldithio)ethaneamine
there is a directcorrelation between the stability of TCR– HCl (PDEA) chemistry to the sensor chip. The surface was activated
ligand binding and the range of biological activities ob- with a 35 ml pulse of NHS/EDC mixture at 5 ml/min, a 35ml pulse of
180 mM PDEA in 0.1 M borate buffer (pH 8.5), and a 35 ml pulse ofserved.
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ethanolamine. Flow was then slowed to 3 ml/min and TCR at 150 and measuring initial on-rates in the presence of inhibitor (Karlsson
1994) is also inappropriate because in this system it is not possiblemg/ml in 10 mM (pH 4.0) sodium acetate was added. Finally, a
mixture of 50 mM cysteine and 1 M sodium chloride was used to to generate mass transport-limited conditions. Therefore, as the
concentration of bound peptide–MHC and TCR in solution (x) isblock the surface. All SPR measurements were conducted at 258C.
Binding kinetics of GPI-linked peptide–Ek complexes were obtained governed by the law of mass action for competition equilibrium:
at 15 ml/min, 20 ml injection, and 10 Hz data collection rate on a
BIAcore (Pharmacia Biosensor) system, and at 30 ml/min, 30 ml (1) (([0 2 x][t0 2 x] 2 KDx)(KDx 1 KD[m0 2 x]) 5 SKM(m0 2 x)x,
injection, and 10 Hz data collection rate for K99R, K99A, and
T102G–Ek complexes on a BIAcore 2000 (Pharmacia Biosensor). where m0 equals (peptide–MHC)solution; t0 equals (TCR)initial equals
1.73 mM; KM equals solution equilibrium dissociation constant forBinding data was fit using the Marquardt–Levenberg nonlinear least
squares algorithm in BIAEvaluation 2.1 (Pharmacia Biosensor) to peptide–MHC and TCR; KD equals surface equilibrium dissociation
constant for MCC–Ek and TCR; and S equals surface concentrationobtain on- and off-rates. For steady-state fitting, the equilibrium
number of resonance units (relative signal on the BIAcore, referred of MCC–Ek equals 179 mM.
The surface concentration, S, of immobilized MCC–Ek was basedto as RU) from K99A–Ek was plotted against its concentration to
calibrate for the linear background level of signal due to refractive on the conversion factor 100 RU 5 1 g/L (Stenberg et al., 1991), the
molecular weight of the immobilized MCC–Ek of 70,000 g/mol, andindex changes associated with the injected protein (Stenberg et
al., 1991). Linear fitting of this curve allowed the calculation of the the approximately 5,000 RU immobilized. In addition, this concentra-
tion was multiplied by the percent of the immobilized material thatbackground level of RU at every concentration of either K99R or
T102G–Ek. The concentration of K99A–Ek was also corrected by had MCC peptide available for binding. This figure was estimated
to be 25% based upon recognition by 14-4-4 and D-4. At 50%normalizing the level of signal in the control blank (PDEA-activated
and cysteine-deactivated) flowcell between K99A and T102G or inhibition (m0 5 IC50), equation 1 simplifies in terms of r2, or the half-
maximal fractional occupancy of the surface immobilized MCC–EkK99R–Ek complexes (to assure that all of the signal seen with antago-
nist peptide–Ek versus K99A–Ek over the TCR surface was due to by TCR:
real binding and not to differences in concentration or nonspecific
interactions with the surface). The steady-state equilibrium model (2) (1 2 r2)(t0 [KM[1 2 r2] 1 ([KDr2] 2 [IC50]KDr2]) 5
(KDr2 1 Sr2[1 2 r2])(KM[1 2 r2] 1 KDr2).in BIAEvaluation 2.1 (Pharmacia Biosensor) was used to fit the equi-
librium level of bound RU of MCC, T102G, or K99R after subtraction
Using the observed IC50 for MCC–Ek in solution of 8.1 mM and settingof the K99A–Ek signal to obtain a KD. For fitting the antagonist pep-
tide–Ek complexes, the maximal response, RUmax, was set to 550 KD and KM equal to 40 mM for MCC–Ek the equation for r2 can be
solved to give r2 5 0.0076. Using the IC50 values for K99R, T102G,RU, estimated to be the maximal level based on several independent
fittings with both MCC and T102S–Ek complexes. By calculating and K99QEk complexes (determined from at least two independent
experiments) in equation 2 then allows the determination of theirRUmax with these higher affinity complexes, the difficulties associ-
ated with fitting only the lower data values on an equilibrium binding equilibrium dissociation constants.
curve with the antagonist peptide–Ek complexes could be reduced.
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